Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA12 | O43570 | 7/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.39 |
| ▸ | FGF1 | P05230 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948805 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL22121795 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL8003273 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL7049511 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL1116554 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL29993884 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL1116557 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL1116556 | 1.00 | CA2 (0.40) | CA2CA12CA9CA1LGALS3 | |
| Sulfuric Acid SCHEMBL14764221 | 0.98 | CA2 (0.39) | CA2CA12CA9CA1LGALS3 | |
| SCHEMBL8201748 | 0.89 | LGALS3 (0.39) | CA2CA12CA9CA1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205616-A1 | NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES | Progen Pharmaceuticals Limited (AU) | 2010-07-14 | — | — | EP | claimed |
| WO-2009049370-A1 | NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PHARMACEUTICALS LIMITED (AU) | 2009-04-23 | — | — | WO | claimed |
| EP-2668198-A1 | FGF RECEPTOR-ACTIVATING 3-O-ALKYL OLIGOSACCHARIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101605-A1 | FGF RECEPTOR-ACTIVATING 3-O-ALKYL OLIGOSACCHARIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-02 | — | — | WO | disclosed |
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-06-23 | — | — | US | disclosed |
| US-7915227-B2 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-03-29 | — | — | US | disclosed |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | NPC1L1, SGMS2, SGMS1 | CA2 2144/4885CA12 1872/4885CA9 2923/4885 |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | SGMS1, SGMS2, CERT1 | CA2 2346/4885CA12 1285/4885CA9 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.